Valneva SE - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VALN Nasdaq 2830 valneva.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Valneva SE

Valneva Announces Successful Outcome of its Annual General Meeting - Jun 25th, 2026 9:45 am
Valneva Announces Availability of Documentation for its Annual General Meeting - Jun 3rd, 2026 11:00 pm
VALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026 - Jun 3rd, 2026 10:00 am
Valneva to Participate at U.S. and European Investor Conferences in June - May 28th, 2026 9:45 am
Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ... - May 13th, 2026 5:00 pm
Valneva Q1 Earnings Call Highlights - May 13th, 2026 1:10 pm
Transcript: Valneva Q1 2026 Earnings Conference Call - May 13th, 2026 9:51 am
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates - May 12th, 2026 11:00 pm
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026 - May 6th, 2026 3:36 am
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026 - May 5th, 2026 10:30 am
Valneva Announces the Successful Completion of an €84 million Reserved Offering - Apr 29th, 2026 11:15 pm
Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13 - Apr 19th, 2026 6:10 pm
Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data - Apr 7th, 2026 8:32 am
Declaration of shares and voting rights of Valneva SE – March 2026 - Apr 3rd, 2026 12:30 am
Will Pfizer’s Lyme disease gamble pay off or set the space back? - Apr 1st, 2026 2:00 am
Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends - Mar 30th, 2026 12:08 am
Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story? - Mar 27th, 2026 7:07 am
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data - Mar 26th, 2026 7:15 pm
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC - Mar 26th, 2026 10:45 am
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study - Mar 24th, 2026 10:12 am